Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In

This article was originally published in Start Up

Executive Summary

In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."

You may also be interested in...



START-UP’s 2013 Life Science Venture Capital Survey: Lights, Even Exits, At The End Of A Dark Tunnel

Our third annual survey of institutional and corporate VCs arrives as life science investing reaches a crossroads. Public markets are gung ho for new biotech companies, lifting the spirits of a subset of our respondents, but VCs still face big hurdles to raise new funds.

Financings Of The Fortnight Looks For A Strong IPO Year To Pick Up Further In Second Half

Looking ahead to Start-Up’s third annual life science venture survey, optimism seems on the upswing and FOTF looks for an even stronger pace of IPOs in the second half of 2013. Plus news on financings by Agios, Merrimack, OncoMed and Alcresta.

Venture Capital Survey Paints Bleak Portrait

A poll of 100 life science VCs reveals fears of industry contraction, increased importance of corporate investors, and attitudes on regulators, therapeutic areas and new investment models.

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel